Skip to main content
  • Register
  • Help
  • Contact us

Ipsen (IPN) Eur1

Sell:€79.70 Buy:€80.00 Change: €0.68 (0.86%)
Market closed |  Prices as at close on 22 April 2021 | Switch to live prices |
Sell:€79.70
Buy:€80.00
Change: €0.68 (0.86%)
Market closed |  Prices as at close on 22 April 2021 | Switch to live prices |
Sell:€79.70
Buy:€80.00
Change: €0.68 (0.86%)
Market closed |  Prices as at close on 22 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Contact details

Address:
65 Quai Georges Gorse
BOULOGNE-BILLANCOURT
92100
France
Telephone:
+33 (1) 58335000
Website:
https://www.ipsen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IPN
ISIN:
FR0010259150
Market cap:
€6.64 billion
Shares in issue:
82.96 million
Sector:
Pharmaceuticals
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Marc de Garidel
    Chairman of the Board
  • David Loew
    Chief Executive Officer, Director
  • Antoine Flochel
    Vice Chairman of the Board
  • Aymeric le Chatelier
    Chief Financial Officer, Executive Vice President
  • Regis Mulot
    Chief Human Resource Officer, Executive Vice President
  • Dominique Laymand
    Executive Vice President, Chief Ethics and Compliance Officer
  • Francois Garnier
    Executive Vice President, General Counsel
  • Dominique Bery
    Executive Vice President, Strategy and Transformation
  • Benoit Hennion
    Executive Vice President and President, Consumer Healthcare
  • Steven Hildemann
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.